While there have so far been no clinical trials using BET inhibitors in bladder cancer, a 2019 in vitro study by Li et al. reported the suppression of urothelial cancer cells by the BET inhibitor JQ1, an analogue of TEN-010 [82]. This evidence concerns the gene DNER and urinary bladder carcinoma.